Switchpoint Bio has raised $5.3M in pre-seed funding from Treehouse Delmar Investments. The biotechnology company decodes cellular biology from blood, using epigenomics and AI to analyze DNA methylation patterns.
That platform is built to reveal immune cell states and the changes tied to disease and treatment, giving drug developers and clinical researchers what the company calls decision-grade evidence.









